Company news

CSL Limited news in 2025

CSL Limited's news releases, calls and decks from 2025, newest first.

View company

Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years

December 7, 2025

CSL to invest approximately $1.5b in U.S. to manufacture plasma-derived therapies

November 18, 2025

CSL Capital Markets Day

November 4, 2025

Seqirus and Vaccine Industrial Company sign landmark Memorandum of Understanding with Ministry of Health to localize manufacturing of cell-based seasonal and pandemic influenza vaccines

October 30, 2025

CSL 2025 AGM Chair and CEO Speech and Presentation

October 27, 2025

CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)

October 26, 2025

Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines

October 21, 2025

CSL: Seqirus Presents Latest Research Across Leading Seasonal Influenza Vaccine Portfolio at ESWI 2025

October 17, 2025

CSL near-term emissions reduction targets validated by the SBTi

October 16, 2025

CSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance (pCPA) for Public Reimbursement of HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B

October 6, 2025

CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy

September 26, 2025

VarmX Partners With CSL in a Strategic Collaboration and Option Agreement to Develop Novel Investigational Coagulation Treatment

September 16, 2025

CSL partners on new coagulation treatment

September 15, 2025

CSL FY25 Results and Major Strategic Initiatives

August 18, 2025

CSL Results Presentation

August 18, 2025

CSL Statutory Accounts for FY2025

August 18, 2025

Health Canada Has Authorized CSL's ANDEMBRY(R) (garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (HAE)

August 12, 2025

Health Canada Has Authorized CSL's ANDEMBRY® (garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (HAE)

August 8, 2025

U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start

June 16, 2025

England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy

May 23, 2025

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

April 29, 2025

CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)

February 20, 2025

CSL Statutory Accounts for the Half Year Ended 31 Dec 2024

February 10, 2025

Calls in 2025

Decks in 2025